Drug failures often occur through drug-drug interactions involving cytochrome P450s, especially CYP3A4. Designing safer drugs faster requires a sensitive, easy to use technology that can be used for a broad range of applications. Promega's new P450-Glo 3A4 Assay with Luciferin-IPA delivers:
slide 1 of 4

Simple and Fast:
"Add and read" assay protocols with short incubation times.
slide 2 of 4

Highly Selective CYP3A4 Substrates:
Recombinant human P450s were assayed for activity against Luciferin-IPA using the P450-Glo™ method as shown in figure (mean ± SD, n=3).
slide 3 of 4

Sensitive Cell-based Assay- Fresh Human Hepatocytes:
Basal cell activity (untreated fresh human hepatocytes) and induced 3A4 activity (fresh human hepatocytes treated for 48hrs with 10µM rifampicin (rif), 500µM phenobarbitol). Cell were incubated with 4µM luciferin-IPA for 60 minutes.
slide 4 of 4

Inhibition Data Correlates well with Conventional Assays:
CYP3A4 inhibition by 9 known inhibitors was measured with a conventional CYP3A4 assay (testosterone (TS) 6β-hydroxylase) and with the Luciferin-IPA CYP3A4 assay. IC50s were calculated and compared.
©2008. All rights reserved. | Patents, Trademarks and Product Usage Info | Privacy Policy | Contact Us
Promega Corporation | Customer Service: 608-274-4330 | Technical Service: 608-274-4330